Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.